Obesity affects more than 40% of adults in the United States, making it a significant health issue
The new medications, technically known as glucagon-like peptide 1 (GLP-1) receptor agonists, are used to promote substantial weight loss, cause a host of cardiometabolic improvements and treat type 2 diabetes
August 11th, 2025: Research Suggests Possible Muscle Weakness Risks from Ozempic A new study from the University of Utah Health raises concerns about potential muscle-related effects of GLP-1 drugs, noting reduced strength in certain muscles despite little change in muscle size
Price: Rs 11,200 / PieceGet Latest Price Product Details: Wegovy FlexTouch 1 mg is a once-weekly semaglutide injection used for long-term weight management in adults and adolescents aged 12 years and older with obesity or overweight and at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia, and it also reduces the risk of major adverse cardiovascular events like heart attack, stroke, and cardiovascular death in adults with established cardiovascular disease
Appetite and satiety changes : The most immediate and noticeable change is typically increased appetite
The goal for most adults on GLP-1 medications is at least 80-100 ounces of fluid daily, more in hot weather or if you exercise
